Long-term treatment with acylated analogues of apelin-13 amide ameliorates diabetes and improves lipid profile of high-fat fed mice

Finbarr P. M. O’Harte*, Vadivel Parthsarathy#, Christopher Hogg, Peter R. Flatt

School of Biomedical Sciences, SAAD Centre for Pharmacy and Diabetes, Ulster University, Coleraine, Co. Londonderry, Northern Ireland, United Kingdom

# Current address: College of Life and Natural Sciences, University of Derby, Kedleston Road, Derby, United Kingdom
* fpm.oharte@ulster.ac.uk

Abstract

Previous studies have shown that modified apelin analogues exhibited enzyme resistance in plasma and improved circulating half-life compared to apelin-13. This study investigated the antidiabetic effects of chronic administration of stable long acting fatty acid modified apelin analogues, namely, (Lys8GluPAL)apelin-13 amide and pGlu(Lys8GluPAL)apelin-13 amide, in high-fat fed obese-diabetic mice. Male NIH Swiss mice (groups n = 8) were maintained either on a high-fat diet (45% fat) from 8 to 28 weeks old, or control mice were fed a normal diet (10% fat). When diet induced obesity-diabetes was established after high-fat feeding, mice were injected i.p. once daily with apelin analogues, liraglutide (25 nmol/kg) or saline (controls). Administration of (Lys8GluPAL)apelin-13 amide and pGlu(Lys8GluPAL)apelin-13 amide for 28 days significantly reduced food intake and decreased body weight. Non-fasting glucose was reduced (p < 0.01 to p < 0.001) and plasma insulin concentrations increased (p < 0.01 to p < 0.001). This was accompanied by enhanced insulin responses (p < 0.01 to p < 0.001) and significant reductions in glucose excursion after oral (p < 0.01) or i.p. (p < 0.01) glucose challenges and feeding. Apelin analogues also significantly improved HbA1c (p < 0.01), enhanced insulin sensitivity (p < 0.01), reduced triglycerides (p < 0.001), increased HDL-cholesterol (p < 0.01) and decreased LDL-cholesterol (p < 0.01), compared to high-fat fed saline treated control mice. Cholesterol levels were decreased (p < 0.01) by pGlu (Lys8GluPAL)apelin-13 amide and both apelin treated groups showed improved bone mineral content, reduced fat deposits and increased plasma GLP-1. Daily treatment with liraglutide mirrored many of these changes (not on bone or adipose tissue), but unlike apelin analogues increased plasma amylase. Consumption of O2, production of CO2, respiratory exchange ratio and energy expenditure were improved by apelin analogues. These results indicate that long-term treatment with acylated analogues (Lys8GluPAL)apelin-13 amide and particularly pGlu(Lys8GluPAL)apelin-13 amide resulted in similar or enhanced therapeutic responses to liraglutide in high-fat fed mice. Fatty acid derived apelin analogues represent a new and exciting development in the treatment of obesity-diabetes.
1. Introduction

Type 2 diabetes mellitus (T2DM) is characterised by defective regulation of carbohydrate, lipid and protein metabolism [1]. The biochemical hallmark of T2DM is chronic hyperglycemia resulting from defects in insulin secretion and action [2,3]. More than 425 million people worldwide are affected by the disease which will increase to 628 million by 2045 [4]. This increase is due to improved life expectancy, obesity and an increase in the populations of ethnic groups at higher risk of the disease [5]. For example in the UK there is an increased predisposition of disease in some ethnic populations (e.g. South Asians, Indian and Pakistani) and this could be due to dietary nutritional deficiencies and or reduced levels of habitual physical activity [6,7]. Uncontrolled hyperglycemia leads to macrovascular and microvascular complications such as cardiovascular disease [8] retinopathy, neuropathy and nephropathy [9,10,11]. Persistent lifestyle changes and pharmacological intervention are essential to achieve good metabolic control and reduce the risk of hyperglycemia induced complications.

Visceral obesity is the most common risk factor associated with T2DM and other chronic diseases, including atherosclerosis, arterial hypertension [12]. The modern Western diet coupled with a sedentary lifestyle has led to a pandemic of obesity which is now a severe public health issue [13,14]. Pharmaceutical agents with dual actions to correct hyperglycemia and promote weight are few and far between with only GLP-1 receptor agonists proving to be effective [15,16]. Even then, side-effects such as nausea, pancreatitis and possible cancer risk limit their usefulness [17,18,19]. Thus there is a significant need for development of new multi-faceted pharmaceutical agents, which induce weight loss and decrease both hyperglycemia and associated complications without causing adverse effects.

Apelin is an adipokine and circulating peptide produced and secreted by adipocytes [20]. Several bioactive apelin peptides, including apelin-12, -13, -16, -17, -19 and -36 are products of APLN gene, located on chromosome 11q12 [21] with apelin-13 and apelin-36 being the most abundant and biologically active forms [22]. The human apelin receptor, APJ is ubiquitously present in tissues [21,23] and the apelinergic system has been shown to be involved in multiple metabolic processes including control of glucose homeostasis [24,25,26].

Rapid degradation and short half-life of native apelin isoforms (4–7 min) severely hinders the pharmacological exploitation of apelin peptides [27]. To overcome this problem, we have developed enzyme resistant fatty acid derived analogues of apelin-13 namely (Lys\(^{8}\)GluPAL)apelin-13 amide and pGlu(Lys\(^{8}\)GluPAL)apelin-13 amide [28]. Notably, these analogues have the identical fatty acid moiety conjugated to Lys\(^{8}\) using the same chemical linker as the GLP-1 mimetic, liraglutide [29]. These stable apelin analogues stimulated insulin secretion from clonal pancreatic beta cells, primary culture of isolated mouse islets cells being the most potent of a series of analogues studied [30]. In the present study, metabolic and weight reducing effects of chronic once daily administration of (Lys\(^{8}\)GluPAL)apelin-13 amide and pGlu(Lys\(^{8}\)GluPAL)apelin-13 amide were directly compared to the GLP-1 mimetic, liraglutide using a high-fat fed mouse model diet-induced obesity-diabetes (DIO).

2. Materials & methods

2.1. Peptides

All apelin analogues used in the study were custom made by EZ Biolabs (Carmel, IN, USA) at >95% purity. Purity of the peptides was checked by RP-HPLC and structural identity confirmed by electrospray ionization mass spectrometry as described previously [28]. Briefly, modifications of native apelin-13 peptide were carried out to confer enzyme resistance to prolong the biological activity. Furthermore, a gamma-glutamyl spacer with palmitate adjunct
(GluPAL) was added to the side-chain of apelin Lys$^8$ to promote binding to plasma proteins and reduce renal clearance, thus extending the in vivo bioactivity. These peptides are only known to bind to and activate the APJ receptor and the half-life in vitro was >24 h [28].

2.2. Experimental animals

Male NIH Swiss mice (Harlan UK Ltd., Blackthorne, UK) were housed individually in an air-conditioned room (22 ± 2°C) with relative humidity of 51 ± 5% and a 12 h light: dark cycle (08:00–20:00 h). Drinking water was freely available. Animals were maintained on a high fat diet (45% fat, 20% protein, 35% carbohydrate; percent of total energy 26.15 kJ/g; Dietex International Ltd., Witham, UK) from 8 weeks of age for a total of 150 days to evoke dietary-induced obesity-diabetes (DIO). Another group of mice was maintained on standard rodent diet (10% fat, 30% protein, 60% carbohydrate; percent of total energy 12.99 kJ/g, Trouw Nutrition, Cheshire, UK) and used as a model of normal controls. Similar high-fat diets, containing a large percentage of energy from fat, are used routinely in obesity-diabetes research [31–33].

2.3. Chronic treatment and metabolic effects

Groups of normal control and high-fat fed mice (n = 8) received once daily intraperitoneal injections of either 0.9% saline vehicle (lean and high fat controls) or either (Lys$^8$GluPAL)apelin-13 amide, pGlu(Lys$^8$GluPAL)apelin-13 amide or liraglutide (each at 25 nmol/kg bw) over a 28 day treatment period. Food intake, bodyweight, non-fasting blood glucose and plasma insulin concentrations were measured every 2–3 days. Following the 28 days, 16 h fasted mice were administered with glucose (18 nmol/kg body weight) either intraperitoneally or orally. To measure the insulin sensitivity, hypoglycemic response was measured following administration of insulin (25 U/kg). Blood samples were collected from cut tail tips of mice and blood glucose (Ascencia Contour meter) and HbA$_1c$ (PTS Diagnostic, IN, USA) were measured. Blood was collected into chilled fluoride/heparin-coated microcentrifuge tubes (Sarstedt, Nümbrecht, Germany) and centrifuged (13,000g × 3 min) using a Beckman microcentrifuge (Beckman Instruments, Palo Alto, CA, USA). The resulting plasma was then aliquoted into fresh Eppendorf tubes and stored at −20°C for subsequent biochemical analysis. Fat mass, bone mineral content (BMC) and bone mineral density (BMD) were assessed using the PIXI-mus DEXA scanner. Measurements of indirect calorimetry, energy expenditure and locomotor activity were assessed using comprehensive laboratory animal monitoring system (CLAMS) metabolic chambers as described previously [34]. Although the main intervention study was carried out for a period of 28 days, the various peptide treatments were extended beyond that period to allow for all of the additional investigations to be performed while maintaining the once daily peptide treatment regime. Thus, all post-intervention experiments were performed between day 28 and day 40. On day 28 body weight, glucose and insulin measurements were carried out. The glucose tolerance test (GTT) and other terminal testing like glycated haemoglobin HbA$_1c$, blood biomarkers were conducted between day 28 and 35. The CLAMS analysis was performed between days 36 and 38 where mice were give 24 h to acclimatise and a further 24 h for measurements, as described previously [35]. Terminal blood samples and tissue retrieval was completed on day 40.

2.5. Terminal analysis

At the end of the experimental period (day 40), pancreatic tissues were excised for analysis of insulin content [36,37]. Blood was taken from fasted mice for measurement of lipid profiles including HDL-cholesterol, LDL-cholesterol and triglyceride levels by an ILab 650 Clinical Analyser (Instrumentation Laboratory, Warrington, UK). Amylase activity (Amylase assay kit,
Abcam, UK) and circulating total GLP-1 (ELISA, Millipore, UK) concentrations was measured as described in manufacturer’s protocol [38].

2.6 Ethical standard
All animal experiments were carried out in accordance with the UK Animals (Scientific Procedures) Act 1986 and EU Directive 2010/63/EU for animal experiments and approved by Ulster University Animal Ethics Review Committee. All necessary steps were taken to prevent any potential animal suffering.

2.7. Statistical analysis
All data was analysed with Prism (v.5.0, GraphPad Software Inc. CA, USA) and expressed as mean ± S.E.M. Bodyweight, glucose, insulin and all GTT data were analysed using two-way analysis of variance (ANOVA) followed by the student-Newman-Keuls post-hoc test. Cumulative food intake was analysed using Student’s t-test. Area under the curve (AUC) was calculated using trapezoidal rule with baseline correction. All other data including AUC were analysed using one-way ANOVA. p<0.05 was considered to be statistically significant.

3. Results
3.1. Chronic administration of acylated apelin-13 amide analogues improves metabolic status in high-fat fed mice
A significant decrease in % bodyweight change was noted with all treatment groups compared to lean and high-fat fed saline treated mice (p<0.01 and p<0.001; Fig 1A and 1B). Cumulative energy intake was also significantly decreased in apelin treated mice (27% decrease, P<0.01; Fig 1C). Both acylated apelin-13 amide analogues significantly decreased non-fasted blood glucose (P<0.05 and P<0.01; Fig 1D) and increased non-fasting plasma insulin (P<0.05 and P<0.01; Fig 1E). Liraglutide evoked similar effects although, with the exception of plasma insulin, with latter onset or less durability.

3.2. Chronic administration of acylated apelin-13 amide analogues reduces glycemic excursion in high-fat fed mice
Administration of acylated apelin-13 amide analogues or liraglutide for 28 days, significantly reduced glycemic excursion after an intraperitoneal or oral glucose load (P<0.05 to P<0.001; Fig 2A, 2C, 2E and 2F) and post oral glucose load (P<0.05 to P<0.001; Fig 2E and 2F). pGlu(Lys^8GluPAL)apelin-13 amide was the most effective as treated mice showed no significant difference in overall glucose excursion compared to lean control mice (Fig 2B). The peptide treatments also significantly increased the overall plasma insulin response after intraperitoneal (P<0.01 and P<0.001; Fig 2C and 2D) or oral glucose load (P<0.05 and P<0.01; Fig 2G and 2H). The insulinotropic responses were much greater than in mice fed on a normal diet (P<0.001, Fig 2D and 2H). Similarly, both acylated apelin-13 amide analogues and liraglutide significantly reduced the blood glucose excursion after 15 min feeding (P<0.05 and P<0.01; Fig 3A). The two acylated apelin-13 amide analogues but not liraglutide significantly increased the plasma insulin response to feeding (P<0.05; Fig 3B). The mean food intake was 0.62, 0.55 and 0.45 g with (Lys^8GluPAL)apelin-13 amide, pGlu(Lys^8GluPAL)apelin-13 amide or liraglutide groups, respectively. Insulin sensitivity in all three treatment groups of mice was improved compared with high-fat fed controls (P<0.05 and P<0.01; Fig 3C).
3.3. Chronic administration of acylated apelin-13 amide analogues improves terminal biomarkers in high-fat fed mice

Both acylated apelin-13 amide analogues and liraglutide produced a significant reduction in HbA1c concentration (P<0.05 to P<0.01; Fig 4A). Furthermore, liraglutide (P<0.05), (Lys8-GluPAL)apelin-13 amide (P<0.05), pGlu(Lys8GluPAL)apelin-13 amide (P<0.001) and liraglutide (P<0.05), all significantly reduced circulating triglyceride concentrations (Fig 4C), with only pGlu(Lys8GluPAL)apelin-13 amide reducing total cholesterol (P<0.01; Fig 4B). Both acylated apelin-13 amide analogues (P<0.01) significantly increased circulating HDL-cholesterol (Fig 4D) compared to either lean or saline-treated high-fat fed mice. In addition, treatment with (Lys8GluPAL)apelin-13 amide (P<0.05) or pGlu(Lys8GluPAL)apelin-13 amide (P<0.01) significantly reduced LDL-cholesterol compared to high-fat fed controls (Fig 4E). Such actions were absent from liraglutide treated mice.
3.4 Chronic administration of acylated apelin-13 amide analogues increases total GLP-1, bone mineral content and reduces fat mass

Chronic administration of liraglutide significantly increased circulating α-amylase compared to both saline and normal lean mice (P < 0.05; Fig 5A). The two acylated apelin-13 amide analogues had no significant effect on this marker of pancreatitis. All treated groups showed enhanced total plasma GLP-1 concentrations (151% - 192%, P < 0.001; Fig 5B). Liraglutide was the only treatment to increase pancreatic insulin content (P < 0.05; Fig 5C). However, both liraglutide (P < 0.01) and pGlu(Lys<sup>8</sup>GluPAL)apelin-13 amide (P < 0.05) treated mice developed significantly greater pancreatic insulin stores compared to lean mice. The percentage fat mass was significantly decreased in apelin treated groups compared to high-fat fed controls (P < 0.05; Fig 5E). Similarly, both apelin analogues significantly increased bone mineral content (BMC) compared to both high-fat fed controls (P < 0.01; Fig 5F), as well as lean mice (P < 0.05; Fig 5F).
3.5 Chronic administration of acylated apelin-13 amide analogues improves indirect calorimetry, energy expenditure, locomotor activity and feeding bouts in high-fat fed mice

Overall oxygen consumption (VO$_2$) in high-fat fed mice were unaffected by any of the three peptide treatments (Fig 6A and 6B). Whereas carbon dioxide production VCO$_2$ was significantly increased ($p < 0.05$; Fig 6C and 6D) by all three treatments. Liraglutide ($p < 0.01$), and both acylated apelin-13 analogues ($p < 0.05$) also significantly increased average respiratory exchange ratio (RER; Fig 7A and 7B) due to higher activity overall (Fig 7B) as well as during the dark cycle (Fig 7D) but not the light cycle (Fig 7C). These peptide treatments also increased energy expenditure ($p < 0.05$; Fig 8A and 8B) evident from changes during both the light and dark cycles ($p < 0.05$; Fig 8C and 8D). In general, the apelin analogues were more effective at promoting increased energy expenditure than liraglutide when compared against the high fat fed saline treated controls (Fig 8B and 8D). The effects on energy metabolism should be beneficial for weight loss if they can be translated in the human situation. No significant effects were observed in the locomotor activity of any of the peptide treated mice when compared to normal mice of saline treated high fat controls (Fig 9A–9F). In contrast to liraglutide, both groups of apelin treated mice exhibited decreased ($p < 0.05$) cumulative food and energy intake over 24 h (Fig 10A and 10B). In the case of the acylated analogue (LysªGluPAL)apelin-13 amide
this was accompanied by decreased energy intake (p < 0.05) and a significantly lower number of feeding bouts (p < 0.05; Fig 10C).

4. Discussion

Numerous studies indicate an emerging involvement of apelin in energy metabolism and the pathophysiology of obesity [39–42]. Both apelin and APJ receptors are present in many tissues including mouse, human and rat adipose tissue and pancreatic islets [20;34,43,44]. Circulating apelin concentrations are increased in obese humans and rodent models of obesity only when accompanied by hyperinsulinaemia [20,45]. This indicates that obesity or high-fat feeding may not be the main cause of elevated apelin, and implies that a close relationship exists between apelin and both the secretion and action of insulin. This highlights possible values of apelin/ APJ interactions as an intriguing therapeutic target for obesity and diabetes.

Consistent with this view, recent work in our laboratory has shown that therapeutic natural and stable analogues of apelin-13 stimulate insulin secretion, enhance cellular glucose uptake and improve acute glucose tolerance in animal models of obesity-diabetes [27,34]. Native
apelin undergoes extensive enzymatic degradation and rapid plasma clearance in vivo. However, structural modifications by addition of fatty acid, amide group and/or N-terminal pyroglutamate residue, resulted in bioactive analogues that displayed an enzyme resistant and greatly extended plasma half-life with greater duration of antihyperglycemic actions [28,30,34].

In the present study, examining the antidiabetic potential in high fat fed mice, we chose to use second generation analogues, namely (Lys8GluPAL)apelin-13 amide and pGlu(Lys8GluPAL)apelin-13 amide. Once daily administration of these peptides for 28 days was associated with robust insulin secretory actions resulting in decreased blood glucose and reduced glucose concentrations, reduced glycemic excursions in response to intraperitoneal or oral glucose tolerance studies and elevated pancreatic insulin content. This was accompanied by significantly reduced levels of HbA1c. The reduction of may also reflect improvement in insulin action as evidenced by enhanced hypoglycemic action of exogenous insulin. An increase of glucose uptake by skeletal muscle and adipose tissue seems likely [34,46]. Indeed, both (Lys8-gluPAL)apelin-13 amide and pGlu(Lys8-gluPAL)apelin-13 amide have been shown to significantly enhance glucose uptake by 3T3-L1 adipocytes in vitro [30] corroborating these findings.
Consistent with this apelin increased glucose uptake, both in vitro [30,47] and in vivo, through both insulin-dependent and independent pathways [46].

In addition to effects on glucose homeostasis (Lys<sup>8</sup>GluPAL)apelin-13 amide and pGlu(Lys<sup>8</sup>GluPAL)apelin-13 amide significantly reduced food intake and evoked significant body weight loss. These actions together with direct effects discussed above, would also be expected to contribute to the improvements of insulin sensitivity and metabolic control. Further studies using pair-feeding might help assess the relative importance of body weight loss but are difficult to interpret due to effects of ‘meal feeding’ on the parameters under investigation. Apelin and its

https://doi.org/10.1371/journal.pone.0202350.g006
APJ receptors have been detected in the arcuate and paraventricular nuclei of hypothalamus, known to be key sites in central control of feeding behaviour and energy expenditure [34,48]. Apelin could also alter body adiposity independent of food intake by increasing energy expenditure through activation of mitochondrial uncoupling proteins 1 and 3 [49].

It is also notable that as observed previously [34] these analogues of apelin-13 (increased plasma levels of total GLP-1 suggesting that enhanced secretion of GLP-1 plays a role in the enhanced beta-cell function and glucose homeostasis. The peptide may also contribute to the reduction of food intake and body weight loss via central affects or action to reduce gastric emptying [34]. Interestingly, apelin knockout (KO) mice exhibit reduced insulin sensitivity,

Fig 7. Effect of once daily i.p. administration of liraglutide, (Lys⁸GluPAL)apel-13 amide or pGlu(Lys⁸GluPAL)apel-13 amide (each at 25 nmol/kg bw) on respiratory exchange ratio (RER, A). Following 35 days treatment mice were placed in CLAMS metabolic chambers for 24 h (12 h dark period as shown by the black bar). RER was calculated by dividing VO₂ by VCO₂. Average RER (B), RER in the light (C) and dark cycles (D) are also included. Values represent the mean ± S.E.M. (n = 6) where *p<0.05 and **p<0.01 is compared to high-fat fed saline treated mice and ^p<0.05 and ^^p<0.01 is compared to normal mice.

https://doi.org/10.1371/journal.pone.0202350.g007
glucose intolerance and hyperinsulinaemia [50]. Apelin administration improved insulin sensitivity in these mice with intact APJ receptors [50], with the insulin-sensitising effects continuing for up to 4 weeks, and no evidence of receptor desensitisation.

In high fat fed mice pGlu(Lys\(^8\)GluPAL)apelin-13 amide reduced total cholesterol in high-fat fed mice. Both the fatty acid apelin analogues had positive effect on reducing circulating triglycerides, LDL-cholesterol as well as increasing HDL-cholesterol. Cardiovascular benefits of apelin, including reduction of blood pressure are well established [51] and further studies...
would be worthwhile to explore such actions in the present context. Once daily administration of the GLP-1 mimetic, liraglutide replicated all of the benefits of apelin-13 analogues but it failed to completely improve lipid profile in high-fat fed mice as shown previously in our lab [38]. Moreover, increased levels of circulating amylase were observed compared to both lean and high-fat fed control, suggesting adverse reactions indicative of pancreatitis [52].

All treated groups including those receiving liraglutide showed increased consumption of \( \text{O}_2 \) and production of \( \text{CO}_2 \), concomitant with increased energy expenditure. This effect on whole body metabolism was associated with reduction of fat mass. Average respiratory exchange ratio was increased in all groups partly reflecting fat depletion as shown previously with apelin analogues [34]. Apelin analogues were superior to liraglutide in improving bone mineral density, thus negating deteriorating effect of fat mass and body weight. Interestingly, fatty acid apelin analogues showed no changes in ambulatory activity in treated mice suggesting weight loss was independent of activity.

**Conclusion**

In conclusion, the present study has shown that once daily administration of \((\text{Lys}^8\text{GluPAL})\text{apelin-13 amide} \) or \(\text{pGlu(Lys}^8\text{GluPAL})\text{apelin-13 amide}\) ameliorated diabetes, evoked weight loss...
and decreased circulating lipids in high-fat fed mice, with effects similar to or better than liraglutide. Overall the pGlu(Lys\textsuperscript{8}GluPAL)apelin-13 amide analogue was the most effective analogue and was better than the non-acylated analogue tested previously [34].

**Author Contributions**

**Conceptualization:** Finbarr P. M. O’Harte.

**Data curation:** Christopher Hogg.
Formal analysis: Christopher Hogg.
Funding acquisition: Finbarr P. M. O’Harte.
Investigation: Vadivel Parthsarathy, Christopher Hogg.
Methodology: Christopher Hogg.
Project administration: Peter R. Flatt.
Supervision: Finbarr P. M. O’Harte, Peter R. Flatt.
Writing – original draft: Vadivel Parthsarathy, Christopher Hogg.
Writing – review & editing: Finbarr P. M. O’Harte, Peter R. Flatt.

References

1. ADA. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2018. Diabetes Care. 2018; 41(Suppl. 1): S13–S27. https://doi.org/10.2337/dc18-S002 PMID: 29222373
2. Kahn SE, Prigeon RL, McCulloch DK, Boyko EJ, Bergman RN, Schwartz MW, et al. Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function. Diabetes. 1993; 42: 1663–1672. PMID: 8405710
3. Holst JJ, Knop FK, Vilsbøll T, Kraan T, Madsbad S. Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes Diabetes Care. 2011; 34: S251–257. https://doi.org/10.2337/dc11-s227 PMID: 21252464
4. Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW, et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045 (8th Edition). Diabetes Res Clin Pract. 2018; pii: S0168-8227(18)30203-1. http://www.diabetesatlas.org/ Accessed 19th March 2018.
5. DeFronzo RA, Ferrannini E, Groop L, Henry RR, Herman WH, Holst JJ, et al. Type 2 diabetes mellitus. Nat Rev Dis Primers. 2015; 1: 15019. Review. https://doi.org/10.1038/nrdp.2015.19 PMID: 27189025
6. Hayes L, White M, Unwin N, Bhopal R, Fischbacher C, Harland J, et al. Patterns of physical activity and relationship with risk markers for cardiovascular disease and diabetes in Indian, Pakistani, Bangladeshi and European adults in a UK population. J Public Health Med. 2002; 24: 170–178. PMID: 12831085
7. Thomas C, Nightingale CM, Donin AS, Rudnicka AR, Owen CG, Sattar N, et al. Socio-Economic Position and Type 2 Diabetes Risk Factors: Patterns in UK Children of SouthAsian, Black African-Caribbean and White European Origin. PLoS One 2012; 7(3):e32619. https://doi.org/10.1371/journal.pone.0032619 PMID: 22412897
8. Mazzone T, Chait A, Plutzky J. Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies. Lancet. 2008; 371: 1800–1809. https://doi.org/10.1016/S0140-6736(08)60768-0 PMID: 18502305
9. Fong DS, Aiello L, Gardner TW, King GL, Blankenship G, Cavallero JD, et al. Retinopathy in diabetes. Diabetes Care. 2004; 27: S84–S87. PMID: 14693935
10. Aring AM, Jones DE, Falko JM. Evaluation and prevention of diabetic neuropathy. Am Fam Physician. 2005; 71: 2123–2128. PMID: 15952441
11. Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zeilmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care. 2005; 28: 164–176. PMID: 15616252
12. Savini I, Catani MV, Evangelista D, Gasperi V, Avigliano L. Obesity-associated oxidative stress: strategies finalized to improve redox state. Int J Mol Sci. 2013; 14: 10497–10538. https://doi.org/10.3390/ijms140510497 PMID: 23998776
13. Jeon SM, Kim JE, Shin SK, Kwon EY, Jung UJ, Baek NI, et al. Randomized double-blind placebo-controlled trial of powdered Brassica rapa ethanol extract on alteration of body composition and plasma lipid and adipocytokine profiles in overweight subjects. J Medicinal Food. 2013; 16: 133–138.
14. Loomba R, Sanyal AJ. The global NAFLD epidemic. Nature Rev Gastroenterol Hepatol. 2013; 10: 686–690.
15. Iepsen EW, Torekov SS, Holst JJ. Liraglutide for Type 2 diabetes and obesity: a 2015 update. Expert Rev Cardiovasc Ther. 2015; 13: 753–767. https://doi.org/10.1586/14799072.2015.1054810 PMID: 26106933
16. Ji Q. Treatment Strategy for Type 2 Diabetes with Obesity: Focus on Glucagon-like Peptide-1 Receptor Agonists. Clin Ther. 2017; 39: 1244–1264. https://doi.org/10.1016/j.clinthera.2017.03.013 PMID: 28526416
17. Nauck MA, Kemmeries G, Holst JJ, Meier JJ. Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans. Diabetes. 2011; 60: 1561–1565. https://doi.org/10.2337/db10-0474 PMID: 21430088

18. Bailey CJ. The current drug treatment landscape for diabetes and perspectives for the future. Clin Pharmacol Therapeutics. 2015; 98: 1532–1535.

19. Irwin N, Flatt PR. New perspectives on exploitation of incretin peptides for the treatment of diabetes and related disorders. World J Diabetes. 2015; 6: 1285–1295. https://doi.org/10.4239/wjd.v6.i15.1285 PMID: 21430088

20. Boucher J, Masri B, Daviaud D, Gesta S, Guigne C, Mazzucotti A, et al. Apelin, a Newly Identified Adipokine Up-regulated by Insulin and Obesity. Endocrinology 2005; 146: 1764–1771. https://doi.org/10.1210/en.2004-1427 PMID: 15677759

21. O’Dowd BF, Heiber M, Chan A, Heng HH, Tsui LC, Kennedy JL, et al. A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11. Gene. 1993; 136: 355–360. PMID: 8294032

22. Kawamoto Y, Habata Y, Fukusumi S, Hosoya M, Fuji R, Hinuma S, et al. Molecular properties of apelin: tissue distribution and receptor binding. Biochimica Biophysica Acta 2001; 23: 162–171.

23. Tatemoto K, Hosoya M, Habata Y, Fuji R, Kakegawa T, Zou MX, et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun. 1998; 251: 471–476. https://doi.org/10.1006/bbrc.1998.9489 PMID: 9792798

24. O’Carroll AM, Lollait SJ, Harris LE, Pope GR. The apelin receptor APJ: journey from an orphan to a multifaceted regulator of homeostasis. J Endocrinol. 2013; 219: R13–R35. https://doi.org/10.1530/JOE-13-0227 PMID: 23943882

25. Hu H, He L, Li L, Chen L. Apelin/APJ system as a therapeutic target in diabetes and its complications. Mol Genet Metab. 2016; 119: 20–27. https://doi.org/10.1016/j.mgme.2016.07.012 PMID: 2765000

26. Fournel A, Drougard A, Duparc T, Marlin A, Brierley SM, Castro J, et al. Apelin targets gut contraction to control glucose metabolism via the brain. Gut 2017; 66: 258–269. https://doi.org/10.1136/gutjnl-2015-310230 PMID: 26565000

27. Gerbier R, Alvear-Perez R, Margathe JF, Flahault A, Couvineau P, Gao J, et al. Development of original metabolically stable apelin-17 analogs with diuretic and cardiovascular effects. FASEB J. 2017; 31: 687–700. https://doi.org/10.1002/ff.201600784R PMID: 27815337

28. O’Harte FPM, Parthsarathy V, Hogg C, Flatt PR. Acylated apelin-13 amide analogues exhibit enzyme resistance and prolonged insulin releasing, glucose lowering and anorexic properties. Biochem Pharmacol. 2017; 146: 165–173. https://doi.org/10.1016/j.bcp.2017.10.002 PMID: 28987595

29. Madsen K, Knudsen LB, Agerose H, Nielsen PF, Thogersen H, Wilken M, et al. Structure-activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives: importance of fatty acid length, polarity, and bulkiness. J Med Chem. 2007; 50: 6126–6132. https://doi.org/10.1021/jm070861j PMID: 17975905

30. West D.B., Wagquespack J., McCollister S. Dietary obesity in the mouse: interaction of strain with diet composition. Am. J. Physiol. 1995; 268: R658–R665. https://doi.org/10.1152/ajpregu.1995.268.3.R658 PMID: 7900908

31. Black B.L., Croom J., Eisen E.J., Petro A.E., Edwards C.L., Surwit R.S. Differential effects of fat and sucrose on body composition in A/J and C57BL/6 mice. Metabolism. 1998; 47: 1354–1359. PMID: 9826212

32. Buettner R., Schömerich J., Bollheimer L.C. High-fat diets: modeling the metabolic disorders of human obesity in rodents. Obesity (Silver Spring) 2007; 15: 798–808.

33. Parthsarathy V, Hogg C, O’Harte FPM, Flatt PR. Beneficial long-term antidiabetic actions of N- and C-terminally modified analogues of apelin-13 in diet-induced obese diabetic mice. Diabetes Obes Metabolism. 2018; 20: 319–327.

34. O’Harte FPM, Franklin ZJ, Irwin N. Two novel glucagon receptor antagonists prove effective therapeutic agents in high-fat-fed and obese diabetic mice. Diabetes Obes Metab. 2014; 16(12): 1214–1222. https://doi.org/10.1111/dom.12360 PMID: 25060150

35. Flatt PR, Bailey CJ. Abnormal plasma glucose and insulin responses in heterozygous lean (ob/+) mice. Diabetologia. 1981; 20: 573–574. PMID: 7026332

36. Hasib A, Ng MT, Gault VA, Khan D, Parthsarathy V, Flatt PR, et al. An enzymatically stable GIP/xenin hybrid peptide restores GIP sensitivity, enhances beta cell function and improves glucose homeostasis.
in high-fat-fed mice. Diabetologia. 2017; 60: 541–552. https://doi.org/10.1007/s00125-016-4186-y
PMID: 28004148

38. Millar P, Pathak N, Parthasarathy V, Bjourson AJ, O’Kane M, Pathak V, et al. Metabolic and neuroprotective effects of dapagliflozin and iraglutide in diabetic mice. J Endocrinol. 2017; 234: 255–267. https://doi.org/10.1530/JOE-17-0263 PMID: 28611211

39. Balistreri CR, Caruso C, Candore G. The role of adipose tissue and adipokines in obesity-related inflammatory diseases. Mediators of Inflamm. 2010; 80: 207–208.

40. Alfarano C, Foussal C, Lairet C, Calise D, Attané C, Anesia R, et al. Transition from metabolic adaptation to maladaptation of the heart in obesity: role of apelin. Int J Obes. (Lond.). 2015; 39: 312–320.

41. Bertrand C, Valet P, Castan-Laurell I. Apelin and energy metabolism. Front Physiol. 2015; 6: 115. https://doi.org/10.3389/fphy.2015.00115 PMID: 25914650

42. Schinzari F, Veneziari A, Mores N, Barini A, Di Daniele N, Cardillo C, et al. Beneficial Effects of Apelin on Vascular Function in Patients With Central Obesity. Hypertension. 2017; 69: 942–949. https://doi.org/10.1161/HYPERTENSIONAHA.116.112653 PMID: 28289180

43. Kleinz MJ, Skepper JN, Davenport AP. Immunocytochemical localisation of the apelin receptor, APJ, to human cardiomyocytes, vascular smooth muscle and endothelial cells. Regul Pept. 2005; 126: 233–240. https://doi.org/10.1016/j.regpep.2004.10.019 PMID: 15664671

44. Dray C, Debard C, Jager J, Disse E, Daviaud D, Martin P, et al. Apelin and APJ regulation in adipose tissue and skeletal muscle of type 2 diabetic mice and humans. Am J Physiol Endocrinol Metab. 2010; 298: 1161–1169.

45. Castan-Laurell I, Vítkova M, Daviaud D, Dray C, Kováčiková M, Kovacova Z, et al. Effect of hypocaloric diet-induced weight loss in obese women on plasma apelin and adipose tissue expression of apelin and APJ. Eur J Endocrinol. 2008; 158: 905–910. https://doi.org/10.1530/EJE-08-0039 PMID: 18390990

46. Dray C, Knauf C, Daviaud D, Waget A, Boucher J, Buléon M et al. Apelin stimulates glucose utilization in normal and obese insulin-resistant mice. Cell Metabolism. 2008; 28: 437–445.

47. Zhu S, Sun F, Li W, Cao Y, Wang C, Wang Y, et al. Apelin stimulates glucose uptake through the PI3K/Akt pathway and improves insulin resistance in 3T3-L1 adipocytes. Mol Cell Biochem. 2011; 353: 305–313. https://doi.org/10.1007/s11010-011-0799-0 PMID: 21461612

48. Valle A, Hoggard N, Adams AC, Roca P, Speakman JR. Chronic central administration of apelin-13 over 10 days increases food intake, body weight, locomotor activity and body temperature in C57BL/6 mice. J Neuroendocrinol. 2008; 20: 79–84. https://doi.org/10.1111/j.1365-2826.2007.01617.x PMID: 18081555

49. Higuchi K, Masaki T, Gotoh K, Chiba S, Katsuragi I, Tanaka K, et al. Apelin, an APJ receptor ligand, regulates body adiposity and favors the messenger ribonucleic acid expression of uncoupling proteins in mice. Endocrinology. 2007; 148: 2690–2697. https://doi.org/10.1210/en.2006-1270 PMID: 17347313

50. Yue P, Jin H, Allaud M, Deng AC, Azuma J, Asagami T, et al. Apelin is necessary for the maintenance of insulin sensitivity. Am J Physiol Endocrinol Metab. 2010; 298: 59–67.

51. Mughal A, O’Rourke ST. Vascular effects of apelin: Mechanisms and therapeutic potential. Pharmacol Ther. 2018; pii: S0163-7258(18): 30093–30097.

52. Gler B, Matveyenko AV, Kirakossian D, Dawson D, Dry SM, Butler PC. Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model. Diabetes 2012; 61: 1250–1262. https://doi.org/10.2337/db11-1109 PMID: 22266669